Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response

Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk A-C, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Núñez NG, Alberti C, da Costa Pereira S, Merten CH, […], Boerries M, […], Zeiser R: Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response. Br J Haematol; doi: 10.1111/bjh.19007 (2023).

Categorised in:

This post was written by redakteur